Claims
- 1. A composition of matter selected from:
a) a substantially pure or recombinant DCRS2 polypeptide comprising at least three distinct nonoverlapping segments of at least four amino acids identical to segments of SEQ ID NO: 2; b) a substantially pure or recombinant DCRS2 polypeptide comprising at least two distinct nonoverlapping segments of at least five amino acids identical to segments of SEQ ID NO: 2; c) a natural sequence DCRS2 comprising mature SEQ ID NO: 2; or d) a fusion polypeptide comprising DCRS2 sequence.
- 2. The substantially pure or isolated antigenic DCRS2 polypeptide of claim 1, wherein said distinct nonoverlapping segments of identity:
a) include one of at least eight amino acids; b) include one of at least four amino acids and a second of at least five amino acids; c) include at least three segments of at least four, five, and six amino acids, or d) include one of at least twelve amino acids.
- 3. The composition of matter of claim 1, wherein said:
a) DCRS2 polypeptide:
i) comprises a mature sequence of Table 1; ii) is an unglycosylated form of DCRS2; iii) is from a primate, such as a human; iv) comprises at least seventeen amino acids of SEQ ID NO: 2; v) exhibits at least four nonoverlapping segments of at least seven amino acids of SEQ ID NO: 2; vi) is a natural allelic variant of DCRS2; vii) has a length at least about 30 amino acids; viii) exhibits at least two non-overlapping epitopes which are specific for a primate DCRS2; ix) is glycosylated; x) has a molecular weight of at least 30 kD with natural glycosylation; xi) is a synthetic polypeptide; xii) is attached to a solid substrate; xiii) is conjugated to another chemical moiety; xiv) is a 5-fold or less substitution from natural sequence; or xv) is a deletion or insertion variant from a natural sequence.
- 4. A composition comprising:
a) a substantially pure DCRS2 and another cytokine receptor family member; b) a sterile DCRS2 polypeptide of claim 1;c) said DCRS2 polypeptide of claim 1 and a carrier, wherein said carrier is:
i) an aqueous compound, including water, saline, and/or buffer; and/or ii) formulated for oral, rectal, nasal, topical, or parenteral administration.
- 5. The fusion polypeptide of claim 1, comprising:
a) mature protein sequence of Table 1; b) a detection or purification tag, including a FLAG, His6, or Ig sequence; or c) sequence of another cytokine receptor protein.
- 6. A kit comprising a polypeptide of claim 1, and:
a) a compartment comprising said protein or polypeptide; or b) instructions for use or disposal of reagents in said kit.
- 7. A binding compound comprising an antigen binding site from an antibody, which specifically binds to a natural DCRS2 polypeptide of claim 1, wherein:
a) said binding compound is in a container; b) said DCRS2 polypeptide is from a human; c) said binding compound is an Fv, Fab, or Fab2 fragment; d) said binding compound is conjugated to another chemical moiety; or e) said antibody:
i) is raised against a peptide sequence of a mature polypeptide of Table 1; ii) is raised against a mature DCRS2; iii) is raised to a purified human DCRS2; iv) is immunoselected; v) is a polyclonal antibody; vi) binds to a denatured DCRS2; vii) exhibits a Kd to antigen of at least 30 μM; viii) is attached to a solid substrate, including a bead or plastic membrane; ix) is in a sterile composition; or x) is detectably labeled, including a radioactive or fluorescent label.
- 8. A kit comprising said binding compound of claim 7, and:
a) a compartment comprising said binding compound; or b) instructions for use or disposal of reagents in said kit.
- 9. A method of producing an antigen:antibody complex, comprising contacting under appropriate conditions a primate DCRS2 polypeptide with an antibody of claim 7, thereby allowing said complex to form.
- 10. The method of claim 9, wherein:
a) said complex is purified from other cytokine receptors; b) said complex is purified from other antibody; c) said contacting is with a sample comprising an interferon; d) said contacting allows quantitative detection of said antigen; e) said contacting is with a sample comprising said antibody; or f) said contacting allows quantitative detection of said antibody.
- 11. A composition comprising:
a) a sterile binding compound of claim 7, or b) said binding compound of claim 7 and a carrier, wherein said carrier is:
i) an aqueous compound, including water, saline, and/or buffer; and/or ii) formulated for oral, rectal, nasal, topical, or parenteral administration.
- 12. An isolated or recombinant nucleic acid encoding said DCRS2 polypeptide of claim 1, wherein said:
a) DCRS2 is from a human; or b) said nucleic acid:
i) encodes an antigenic peptide sequence of Table 1; ii) encodes a plurality of antigenic peptide sequences of Table 1; iii) exhibits identity over at least thirteen nucleotides to a natural cDNA encoding said segment; iv) is an expression vector; v) further comprises an origin of replication; vi) is from a natural source; vii) comprises a detectable label; viii) comprises synthetic nucleotide sequence; ix) is less than 6 kb, preferably less than 3 kb; x) is from a primate; xi) comprises a natural full length coding sequence; xii) is a hybridization probe for a gene encoding said DCRS2; or xiii) is a PCR primer, PCR product, or mutagenesis primer.
- 13. A cell or tissue comprising said recombinant nucleic acid of claim 12.
- 14. The cell of claim 13, wherein said cell is:
a) a prokaryotic cell; b) a eukaryotic cell; c) a bacterial cell; d) a yeast cell; e) an insect cell; f) a mammalian cell; g) a mouse cell; h) a primate cell; or i) a human cell.
- 15. A kit comprising said nucleic acid of claim 12, and:
a) a compartment comprising said nucleic acid; b) a compartment further comprising a primate DCRS2 polypeptide; or c) instructions for use or disposal of reagents in said kit.
- 16. A nucleic acid which:
a) hybridizes under wash conditions of 30 minutes at 30° C. and less than 2M salt to the coding portion of SEQ ID NO: 1; or b) exhibits identity over a stretch of at least about 30 nucleotides to a primate DCRS2.
- 17. The nucleic acid of claim 16, wherein:
a) said wash conditions are at 45° C. and/or 500 mM salt; or b) said stretch is at least 55 nucleotides.
- 18. The nucleic acid of claim 16, wherein:
a) said wash conditions are at 55° C. and/or 150 mM salt; or b) said stretch is at least 75 nucleotides.
- 19. A method of modulating physiology or development of a cell or tissue culture cells comprising contacting said cell with an agonist or antagonist of a mammalian DCRS2.
- 20. The method of claim 19, wherein said cell is transformed with a nucleic acid encoding a DCRS2 and another cytokine receptor subunit.
Parent Case Info
[0001] This filing is a U.S. Utility patent application which claims priority to U.S. SNo. 60/137,159, filed Jun. 1, 1999, which is incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60137159 |
Jun 1999 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09588113 |
May 2000 |
US |
Child |
10247463 |
Sep 2002 |
US |